**AUB KQ1 Evidence Table (Reference ID #1184)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Cameron et al., 1987**Country:**United Kingdom**Enrollment** **period:** NR**Intervention** **setting:** Hospital**Funding:**Birthright research grant, Royal College of Obstetricians and Gynaecologists **Author industry relationship disclosures:**NR**Study Design:** RCT**Blinding:** NR | **Intervention:**Mefenamic acid 500 mg three times per day for the first five days of cycle; **Comparator:** Norethisterone 5 mg two times per day on cycle days 15 to 25; Progesterone-impregnated coil releasing 65 mcg progesterone dailyTwo control cycles, two treatment cycles **Groupsa:****G1:** Mefenamic acid**G2:** Norethisterone**G3:** Progesterone-impregnated coil**Followup:**4 months | **Inclusion criteria:** Mean MBL >50 ml**Exclusion criteria:** See inclusion criteria**N at enrollment:** **G1:** 8**G2:** 8**G3:** 8**N at followup:** **G1:** 6**G2:** 7**G3:** 6**Age, median years (range):****G1:** 40 (33, 48)**G2:** 39 (35, 46)**G3:** 40 (29, 42)**BMI:**NR**Weight, median kg (range):****G1:** 64 (50, 70)**G2:** 64 (52, 73)**G3:** 70 (54, 89)**Height, median cm (range):****G1:** 162 (149, 164)**G2:** 164 (152, 169)**G3:** 162 (145, 164)**Parity, median (range):****G1:** 4 (2, 4)**G2:** 4 (1, 4)**G3:** 2 (2, 4)**Race/ethnicity:**NR | **Bleeding:**MBL measured by alkaline hematin method, median ml (range):**G1:** 68 (61, 169)**G2:** 94 (55, 312)**G3:** 71 (56, 164)MBL measured by alkaline hematin method, followup group, median ml (range):**G1:** 85 (68, 169)**G2:** 131 (55, 259)**G3:** 64 (56, 164)Number of bleeding days, median (range):**G1:** 5 (4, 7)**G2:** 6 (4, 7)**G3:** 5 (4, 6)Cycle length, median days (range):**G1:** 28 (23, 38)**G2:** 28 (24, 30)**G3:** 26 (23, 30)Endometrial prostaglandin, median pg/mg (range):**G1:** 412 (256, 9506)**G2:** 770 (152, 2251)**G3:** 842 (265, 1630)  | **Bleeding:**MBL measured by alkaline hematin method, median ml (range):**G1:** 47 (39, 210)**G2:** 110 (24, 222)**G3:** 45 (31, 77)**G1 vs. BL:** p=0.05**G2 vs. BL:** p=NS**G3 vs. BL:** p<0.05Number of bleeding days:No difference vs. baselinebEndometrial prostaglandin, median pg/mg (range):**G1:** 546 (412, 3434)**G2:** 985 (55, 1987)**G3:** 273 (178, 832)**G1 vs. BL:** p=NS**G2 vs. BL:** p=NS**G3 vs. BL:** p=0.05**Quality of life:**NR**Pain:**NR**Sexual function:**NR**Patient satisfaction:**NR**Fertility:**NR**Time to conception:**NR**Additional interventions:**NR**Adverse events:**NR | **Overall quality:**Poor**Risk of bias:** Randomization: UnclearAllocation concealment:UnclearSelective reporting:UnclearBlinding patients/personnel:HighBlinding outcome assessment:HighIncomplete outcome reporting:UnclearOther:Unclear |

**Table Notes**: a Does not include a treatment group randomized to danazol (n=6); b Baseline refers to control cycles.